30
Participants
Start Date
August 25, 2008
Primary Completion Date
June 28, 2023
Study Completion Date
April 15, 2024
Rituximab
Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
Lenalidomide
Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
University of California Davis Cancer Center, Sacramento
Collaborators (1)
Celgene
INDUSTRY
University of California, Davis
OTHER